News

Filter

Current filters:

Seebri Breezhaler

1 to 9 of 10 results

Further evidence of Ultibro Breezhaler efficacy showcased at ERS meeting

09-09-2013

Swiss drug major Novartis (NOVN: VX) released date data from new analyses for once-daily Ultibro Breezhaler…

NovartisPharmaceuticalResearchRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Vectura foresees important catalysts in second half

13-08-2013

Shares of UK-based developer of inhaled therapies Vectura (LSE: VEC) rose 1.6% to 96 pence in mid-morning…

EuropeFinancialPharmaceuticalRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

New data from Novartis on QVA149 and Seebri Breezhaler at ERS

03-09-2012

Further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs…

NovartisPharmaceuticalQVA149ResearchRespiratory and PulmonarySeebri BreezhalerVectura

Novartis set to file QVA149 filing in EU and Japan by end of year

31-08-2012

Swiss drug major Novartis announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium…

NovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonarySeebri BreezhalerVectura

Vectura updates on developmental products and milestones

15-08-2012

UK-based Vectura (LSE: VEC) saw its share price rise 4.9% to 75.50 pence yesterday morning, after the…

FinancialPharmaceuticalResearchRespiratory and PulmonarySeebri BreezhalerVectura

Positive outlook for Vectura, as Seebri Breezhaler closer to EU approval

02-08-2012

UK-based inhalation product development company Vectura (LSE: VEC) is a step closer to European approval…

FinancialNovartisPharmaceuticalRegulationRespiratory and PulmonarySeebri BreezhalerVectura

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top